Skip to main content

Table 3 Genome-wide association studies of antidepressant treatment response

From: Genome-wide approaches to antidepressant treatment: working towards understanding and predicting response

Sample GWAS sample size (N) Microarray used Primary outcome measure Response phenotype definition SNPs reaching suggestive levels of significance (nearest gene)
STAR*D [5] 1,948 Affymetrix 500K/5.0 human SNP arrays QID-SR Response: >50% reduction in score rs6966038 (UBE3C), rs6127921 (BMP7), rs809736 (RORA)
     Remission: score <5   
MARS [9] 339 (two replication samples, N=361 and N=831) Sentrix Human-1 and HumanHap300 BeadChip HAM-D Early partial response: >25% reduction in score after 2 weeks of treatment rs6989467 (CDH17)a, rs1502174 (EPHB1)
     Response: >50% reduction in score   
     Remission: score <10   
GENDEP [13] 706 Illumina 610 array MADRS Percentage change from baseline to week 12 Whole-sample analysis rs2136093, rs6701608 and rs2136094 (intergenic, on chromosome 1)rs16920624, rs11598854 and rs7081156 (intergenic, on chromosome 10)
      Escitalopram-specific analysis rs1126757 (IL11)
      Nortriptyline-specific analysis rs2500535 (UST)
      Gene-by-drug analysis rs2500535 (UST)
  1. aOnly associated with early partial response. GWAS, genome-wide association study; HAM-D, Hamilton Depression Rating Scale; MADRS, Montgomery-Asberg Depression Rating scale; QID-SR, Quick Inventory of Depressive Symptomatology Self-Report version; SNP, single nucleotide polymorphism.